Skip to main content
Black Health logo Black Health
Respiratory Last reviewed:

Asthma

Also known as: Reactive airway disease, Bronchial asthma

Reviewed by the Black Health editorial team Last reviewed

7.7x

asthma death rate, Black vs. white children (CDC, 2021 NHIS)

Overview

Asthma is common across all American communities, but its consequences are not equally distributed. Black children die from asthma at a rate 7.6 times higher than white children. Black adults die from asthma at nearly 3 times the rate of white adults. These are not statistical artifacts; they reflect a gap between a manageable condition and the care that actually reaches Black patients. This page explains the numbers, the biological and structural reasons they exist, what effective treatment looks like, and how to get it.

How Asthma affects Black patients

The clinical numbers are not subtle. Using 2020 healthcare-utilization data, Black children had 89.5 emergency department visits per 10,000 for asthma, compared with 14.4 per 10,000 among white children, roughly a 6-fold difference, and 8.6 inpatient stays per 10,000 versus 1.5 (Pate and Zahran, 2024). Black adults had 80.6 ED visits per 10,000 versus 27.8 for the total population, and asthma mortality of 29.7 per million versus 13.1 overall.

Three drivers account for most of that gap, and none are genetic in the lay sense.

First, where people live. The 2022 Pittsburgh registry study by Schuyler and Wenzel (American Journal of Respiratory and Critical Care Medicine, 2022, PMID 35612914) linked 1,034 asthma patients to historical Home Owners' Loan Corporation maps from the 1930s. Neighborhoods graded D, the redlined zones that were disproportionately Black, showed elevated PM2.5, sulfur dioxide, carbon monoxide, and VOC emissions almost a century later. Black participants living in grade-D tracts carried a relative risk of 2.30 for uncontrolled or severe asthma compared with Black participants in higher-graded tracts. The mechanism is concrete: diesel highway corridors, industrial sites, port traffic, and older housing stock with mold and cockroach allergens cluster inside lines that federal appraisers drew on purpose.

Second, bronchodilator response is not uniform across ancestry. Burchard's lab at UCSF, working with the SAGE II cohort of 949 African American children with asthma and replicating in 1,325 African American adults from SAPPHIRE, found a chromosome-9 variant (rs73650726) common in African-ancestry populations and rare elsewhere that is associated with reduced response to short-acting beta-agonists (Mak et al., Pharmacogenomics Journal, 2018, PMID 30206298). The clinical translation: a Black child whose albuterol seems to stop working during an exacerbation may not be exaggerating or using the inhaler wrong. The drug-response curve was built on populations that did not include them.

Third, the SABA-overuse pattern. The SABINA cohort (Nwaru et al., European Respiratory Journal, 2020, PMID 31949111) showed that filling three or more short-acting beta-agonist canisters per year was associated with dose-dependent increases in exacerbations and all-cause mortality, and that 28 percent of overusers were collecting no anti-inflammatory medication at all. In the United States, Black patients are the population most likely to be on a SABA-only regimen with an under-prescribed or unfilled inhaled corticosteroid. If your reliever is still albuterol alone in 2026, the guideline has changed; ask why your prescription has not.

Symptoms

  • Wheeze, especially on exhalation, that wakes you at night or comes on after exercise, cold air, or upper respiratory infections
  • Chest tightness that some patients describe as a band, a weight, or sitting on the chest
  • Cough that lingers for weeks after a cold, or a dry cough that is worse at night or early morning
  • Shortness of breath that is out of proportion to the activity (climbing one flight, walking to the bus stop)
  • A reliever inhaler you reach for more than twice a week, or one canister lasting less than a month
  • In children: recurrent bronchitis, fatigue at recess, missed school days clustered in the fall and spring

When to see a doctor

Same-week visit if you are using a rescue inhaler more than twice a week, waking from sleep coughing or wheezing more than twice a month, or limiting activity because of breathing. Urgent or emergency care if your reliever is not opening you up within 20 minutes, you cannot speak in full sentences, your lips or fingertips look gray or bluish, peak flow is below 50 percent of your personal best, or a child is sucking in between the ribs or above the collarbone with each breath. Black adults and children are disproportionately diagnosed in the ED rather than primary care; do not wait for a crisis to establish a controller plan.

Screening

There is no population screening test for asthma. Diagnosis rests on a compatible history plus objective evidence of variable airflow obstruction. The NHLBI 2020 Focused Updates and the 2007 EPR-3 guidelines both recommend spirometry, pre- and post-bronchodilator, as the diagnostic standard. An FEV1 that rises by 12 percent or more (and at least 200 mL in adults) after albuterol confirms reversibility. Peak flow meters are monitoring tools, not diagnostic ones; reference values vary too widely between devices to be used in isolation for diagnosis, but a peak-flow diary kept over two to four weeks is useful for tracking control. For children under five, diagnosis is clinical: pattern of symptoms, response to a treatment trial, and exclusion of alternatives. Fractional exhaled nitric oxide (FeNO) and methacholine challenge are second-line tests when spirometry is normal but symptoms are convincing.

Treatment overview

The 2024 GINA Strategy Report restructured adult and adolescent treatment around a preferred Track 1: low-dose inhaled corticosteroid combined with formoterol, used both as the daily controller and as the as-needed reliever, anti-inflammatory reliever (AIR) therapy. Across the pooled trial data, low-dose ICS-formoterol reduces severe exacerbations by half to two-thirds compared with SABA alone. SABA-only treatment is no longer recommended for any adult or adolescent with asthma at any severity, including mild disease.

The NHLBI 2020 Focused Updates align with this direction for the U.S., endorsing single maintenance and reliever therapy (SMART) with ICS-formoterol for patients aged four and up with moderate-to-severe disease. Biologic add-ons (omalizumab for IgE-driven disease, mepolizumab/benralizumab/dupilumab for eosinophilic phenotypes, tezepelumab for broader Type 2 and low-T2 disease) are step-5 options when high-dose ICS-LABA plus add-ons fail to control symptoms; eligibility hinges on biomarkers (IgE, blood eosinophils, FeNO) that should be checked before assuming a patient has treatment-resistant asthma. For Black patients specifically, two practical asks: confirm the prescription is ICS-containing and not SABA-only, and confirm the inhaler technique with a pharmacist, because spacer use and inspiratory flow drive whether the drug reaches the small airways at all.

Questions to ask your doctor

Bring this list to your next appointment.

  • Based on how often I (or my child) have symptoms, what step of asthma treatment should we be on?
  • Do I (or my child) have a written asthma action plan? Can we make one at this visit?
  • Should I be on a daily controller medication, or am I only using the rescue inhaler?
  • What are my (or my child's) specific triggers, and has allergy testing been done to identify them?
  • If I am still having flares or visiting the ER despite using controller medications, should I be evaluated for a biologic?
  • Can you review my inhaler technique with me right now to make sure I am using it correctly?
  • Is there a social worker or community health worker who can help assess my home environment for asthma triggers?

Find care for asthma

Not sure where to start? Describe what you're experiencing and we'll help you find the right kind of care, including a pulmonology.

Find care

The numbers

What it is

Asthma is a chronic inflammatory condition of the airways. In people with asthma, the airways are persistently inflamed, making them hypersensitive to certain triggers. When a trigger is encountered, the airway muscles tighten (bronchospasm), the lining swells, and excess mucus is produced. The result is the familiar set of symptoms: wheezing, chest tightness, shortness of breath, and coughing, often worse at night or early morning.

Asthma is not a single disease. It exists on a spectrum from mild intermittent (occasional symptoms with long periods of normal lung function) to severe persistent (daily symptoms, frequent flares, significant lung function impairment). The severity level determines which medications are appropriate.

Asthma is not curable, but it is controllable. A person with well-managed asthma should be able to sleep through the night without symptoms, participate in physical activity normally, miss minimal school or work, and require their rescue inhaler no more than twice a week on most weeks. When these goals are not being met, treatment is inadequate, not the patient's fault.

Why it is different for Black patients

Allergen exposure in housing. The indoor environment is one of the most important modifiable asthma triggers, and it is shaped directly by housing quality. Black families are disproportionately concentrated in older, lower-quality housing with higher levels of cockroach allergen, mouse allergen, mold, and dust mites. A landmark New England Journal of Medicine study established that cockroach allergen sensitivity is one of the strongest predictors of asthma morbidity in inner-city children. (NEJM: The Role of Cockroach Allergy and Exposure to Cockroach Allergen in Causing Morbidity Among Inner-City Children with Asthma, 1997) These exposures are not a matter of individual hygiene; they are a function of building age, landlord maintenance, and neighborhood infrastructure.

Outdoor air quality. Black communities are more likely to be located near highways, industrial facilities, and other pollution sources due to decades of discriminatory zoning and real estate practices. Particulate matter (PM2.5) and ozone are potent asthma triggers; sustained exposure increases both prevalence and severity.

Undertreatment with controller medications. The standard of care for persistent asthma is a daily inhaled corticosteroid (ICS), which reduces the underlying airway inflammation. Studies consistently show Black patients are less likely to be prescribed ICS medications and more likely to rely solely on short-acting beta-agonists (SABAs) like albuterol for rescue. Relying only on a rescue inhaler treats symptoms but does not control the underlying inflammation, which is why hospitalizations and deaths occur: the airway remains primed for a dangerous flare. (PMC: Disparities in Asthma Care, Management, and Education Among Children With Asthma, PMC4999068)

Gaps in asthma education and action plans. A written asthma action plan, a simple one-page document showing what to do at different symptom levels, dramatically reduces emergency visits and hospitalizations. Research shows Black children are less likely to receive written action plans and less likely to have the plan reviewed with caregivers in detail. This is a clinician failure, not a patient behavior problem.

Medical mistrust and system barriers. Historical and ongoing experiences of poor treatment, being dismissed or undertreated in clinical settings, contribute to delayed care-seeking. Emergency department visits are, in part, a consequence of inadequate access to routine primary care and specialist follow-up.

Treatment, plainly

Asthma treatment is organized by severity and uses a step-up approach: start at the appropriate step, evaluate control after 4 to 6 weeks, step up if control is inadequate, step down if control is excellent.

Rescue medication (used by everyone with asthma): A short-acting beta-agonist (SABA), most commonly albuterol, opens the airways within minutes during a flare. It is not a substitute for controller therapy. Using a rescue inhaler more than twice a week most weeks is a signal that controller therapy is inadequate.

Step 1 (mild intermittent): SABA as needed only. No daily controller medication required.

Step 2 (mild persistent): Low-dose inhaled corticosteroid (ICS) daily. This is the single most important class of medication in asthma management. Examples include fluticasone, budesonide, beclomethasone. Fear of steroids is common; ICS medications are inhaled, act locally in the airway, and have a very different safety profile from oral steroids. Long-term use at low to medium doses is safe for children and adults.

Step 3 (moderate persistent): Medium-dose ICS, or low-dose ICS combined with a long-acting beta-agonist (LABA) such as salmeterol or formoterol. Combination inhalers (ICS/LABA in one device) improve adherence.

Step 4 and above (severe persistent): High-dose ICS/LABA combination, with possible addition of long-acting muscarinic antagonists (LAMA, such as tiotropium), oral corticosteroids, and biologic therapies.

Biologics for severe asthma: For patients with severe, poorly controlled asthma despite maximal inhaler therapy, biologic injections have transformed outcomes in the last decade. Options include:

  • Omalizumab (anti-IgE): approved for allergic asthma in patients 6 and older
  • Dupilumab (anti-IL-4/IL-13): approved down to age 6
  • Mepolizumab, benralizumab, tezepelumab: options for eosinophilic severe asthma

These are monthly or bimonthly injections, usually given at an allergist or pulmonologist's office. They reduce exacerbation rates by 50% or more in appropriate patients. If a patient is still being hospitalized or using oral steroids repeatedly despite high-dose inhalers, asking about a biologic is appropriate.

Allergen mitigation at home: When cockroach allergen is the primary trigger (confirmed by allergy testing), integrated pest management in the home, combined with impermeable mattress and pillow covers, can reduce exposure and improve symptoms. These interventions are most effective when paired with medical management.

How to find care

Sources

  1. Office of Minority Health, HHS: Asthma and African Americans
  2. PMC: Disparities in Asthma Care, Management, and Education Among Children With Asthma (PMC4999068)
  3. NEJM: The Role of Cockroach Allergy and Exposure to Cockroach Allergen in Causing Morbidity Among Inner-City Children with Asthma (1997)
  4. CDC: The Status of Asthma in the United States
  5. PMC: The Status of Asthma in the United States (PMC11262137)
  6. ATS: Health Disparities in Asthma
  7. PMC: Sociodemographic Factors of Asthma Prevalence and Costs Among Children and Adolescents in the United States, 2016-2021 (PMC11318947)
  8. EPA: Indoor Environment Workgroup Report on Asthma Disparities
  9. PMC: Housing Interventions and Control of Asthma-Related Indoor Biologic Agents (PMC3934496)
  10. NHLBI: National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Medical disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.

Share:
Find a Black doctor near you